India’s pharmaceutical sector is setting its sights on a 1 trillion USD export target by 2030, with biosimilars positioned as the key driver of this ambitious growth. This vision was outlined during a high-level meeting at the Ministry of Commerce, where officials and representatives from the Pharmaceuticals Export Promotion Council (Pharmexcil) discussed a revamped export strategy focused on high-value, innovation-led therapies.

As reported by The Economic Times, Pharmexcil Chairman Namit Joshi projected that India’s biosimilars segment could exceed 60 billion USD in exports by 2030—accounting for nearly half of the estimated 120–130 billion USD in total pharma exports. The remaining contribution would come from India’s strong generics sector, which currently anchors the country’s 50–55 billion USD pharmaceutical export base.

Leading companies like Biocon, Cipla, and Dr. Reddy’s Laboratories are already investing heavily in expanding their biosimilar portfolios into regulated markets such as the US and EU. Joshi emphasized that while a few players possess the financial and regulatory muscle to compete globally in biologics, broader sectoral growth will require greater investment in biologics, digital therapeutics, and specialty medicines.

The shift toward biosimilars comes amid stagnation in the global generics market, which is growing at just 5% annually. In contrast, biosimilars and innovation-driven products offer faster, higher-margin opportunities. To capture this value, Joshi called for closer alignment between government bodies, manufacturers, and India’s diplomatic missions to support global market access.

Achieving the 1 trillion USD vision will require a compound annual growth rate (CAGR) of 11–12%. This calls for enhanced R&D, regulatory preparedness, and manufacturing scale. With the right public-private partnerships and early investment in complex therapies, India aims to transition from a volume-driven generics leader to a global powerhouse in biosimilars and specialty pharmaceuticals.